(MENAFN- GetNews)
Idiopathic Membranous Nephropathy treatment market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Idiopathic Membranous Nephropathy Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight's“ Idiopathic Membranous Nephropathy Market Insights, Epidemiology and Market Forecast – 2034 ” report delivers an in-depth understanding of Idiopathic Membranous Nephropathy (IMN), historical and forecasted epidemiology as well as the Idiopathic Membranous Nephropathy (IMN) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Unlock detailed insights into the Idiopathic Membranous Nephropathy Market by downloading the comprehensive report from DelveInsight @ Idiopathic Membranous Nephropathy Therapeutics Market
Key Takeaways from the Idiopathic Membranous Nephropathy Market Report
In September 2024:-Shanghai Jiaolian Drug Research and Development Co., Ltd- A Multicenter, Randomized, Controlled, Open Phase II/III Clinical Study to Evaluate the Efficacy and Safety of B007 Versus Cyclosporine in the Treatment of Primary Membranous Nephropathy. To evaluate the efficacy and safety of B007 in the Treatment of Primary Membranous Nephropathy.
In August 2024:- BeiGene- The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to evaluate the efficacy of zanubrutinib compared with tacrolimus as measured by complete remission rate, in participants with primary membranous nephropathy who are on optimal supportive care.
In 2023, the US accounted for ~40% of all Idiopathic Membranous Nephropathy prevalent cases in 7MM.
Japan's data suggests a relatively stable trend in the Idiopathic Membranous Nephropathy prevalence over the forecasted period of 2024-2034.
Germany had the highest Idiopathic Membranous Nephropathy prevalence among EU4 and the UK, accounting for ~30% of cases, followed by the UK with ~20%, in 2023.
In 2023, the PLA2R-specific cases in EU4 and the UK contributed ~75% in the 7MM.
The leading Idiopathic Membranous Nephropathy Companies such as SynAct Pharma Aps, argenx, Shanghai Jiaolian Drug Research and Development Co., Ltd, Beijing Mabworks Biotech Co., Ltd., Cerium Pharmaceuticals, Inc., BeiGene, Reistone Biopharma Company Limited, Hoffmann-La Roche, Alpine Immune Sciences, Inc., Walden Biosciences, and others.
Promising Idiopathic Membranous Nephropathy Therapies such as WAL0921, povetacicept, Belimumab, Obinutuzumab, Methylprednisolone, Tacrolimus, and others.
Gain a competitive edge in the Idiopathic Membranous Nephropathy Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Idiopathic Membranous Nephropathy Treatment Drugs
Idiopathic Membranous Nephropathy Epidemiology Segmentation in the 7MM
Total Idiopathic Membranous Nephropathy prevalent cases
Idiopathic Membranous Nephropathy antigen-specific cases
Total Idiopathic Membranous Nephropathy treated cases
Idiopathic Membranous Nephropathy Market Insights
Membranous nephropathy (MN) is an autoimmune disease caused by antibodies mostly directed to podocyte antigens and characterized by very high levels of protein in the urine, edema, hypoalbuminemia, and elevated serum lipids. MN is typically divided into primary MN (Idiopathic membranous nephropathy) when there is no underlying disease association and secondary MN when there is an underlying disease association such as autoimmune disease (most commonly lupus), malignancy, infection, or temporal association with the use of certain drugs. The short-term goal of treatment is to stop protein spillage completely (known as remission) or lower the amount of protein lost in the urine as much as possible. The less protein lost in the urine, the better the individual will do. The long-term treatment goals, including protein relapses in the urine and preventing the deterioration of kidney function.
Discover key developments and opportunities in the Idiopathic Membranous Nephropathy Market. Click here to learn more from DelveInsight's latest report @ Idiopathic Membranous Nephropathy Market Size
Idiopathic Membranous Nephropathy Emerging Drugs
GAZYVA (obinutuzumab): Hoffmann-La Roche
SNP-ACTH (1-39) Gel: Cerium Pharmaceuticals
Idiopathic Membranous Nephropathy Drugs Uptake
Idiopathic Membranous Nephropathy pipeline possesses some drugs in mid- and late stage developments to be approved in the near future. Expected launch of emerging therapies, such as GAZYVA (obinutuzumab) by Hoffmann-La Roche, MOR202 (felzartamab) by MorphoSys/HI-Bio, MOR202 (felzartamab) by MorphoSys/HI-Bio, BRUKINSA (zanubrutinib) by BeiGene and others shall further create a positive impact on the market.
Download DelveInsight's Idiopathic Membranous Nephropathy Market report today and stay ahead in this rapidly evolving field. @ Idiopathic Membranous Nephropathy Clinical Trials
Scope of the Idiopathic Membranous Nephropathy Market Report
Coverage- 7MM
Idiopathic Membranous Nephropathy Companies- SynAct Pharma Aps, argenx, Shanghai Jiaolian Drug Research and Development Co., Ltd, Beijing Mabworks Biotech Co., Ltd., Cerium Pharmaceuticals, Inc., BeiGene, Reistone Biopharma Company Limited, Hoffmann-La Roche, Alpine Immune Sciences, Inc., Walden Biosciences, and others.
Idiopathic Membranous Nephropathy Therapies- WAL0921, povetacicept, Belimumab, Obinutuzumab, Methylprednisolone, Tacrolimus, and others.
Idiopathic Membranous Nephropathy Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Idiopathic Membranous Nephropathy Unmet Needs, KOL's views, Analyst's views, Idiopathic Membranous Nephropathy Market Access and Reimbursement
Download the report to understand which factors are driving Idiopathic Membranous Nephropathy Market Trends @ Idiopathic Membranous Nephropathy Market Trends
Table of Content
1. Key Insights
2. Report Introduction
3. Idiopathic Membranous Nephropathy (IMN) Market Overview at a Glance
4. Methodology
5. Executive Summary of IMN
6. Key Events
7. Disease Background and Overview
8. Treatment and Management
9. Epidemiology and Patient Population
10. Patient Journey
11. Emerging Therapies
12. Market Analysis
13. KOL Views
14. SWOT Analysis
15. Unmet Needs
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
MENAFN17092024003238003268ID1108685342
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.